Treatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statement

1998 1998 2001 Chopra, 2003, Antibiotic resistance in Staphylococcus aureus: concerns, causes and cures, Expert Rev Anti Infect Ther, 1, 45, 10.1586/14787210.1.1.45 Hancock, 2005, Mechanisms of action of newer antibiotics for Gram-positive pathogens, Lancet Infect Dis, 5, 209, 10.1016/S1473-3099(05)70051-7 Zetola, 2005, Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat, Lancet Infect Dis, 5, 275, 10.1016/S1473-3099(05)70112-2 Leavis, 2006, Identification of high-risk enterococcal clonal complexes: global dispersion and antibiotic resistance, Curr Opin Microbiol, 9, 454, 10.1016/j.mib.2006.07.001 Pankey, 2005, Tigecycline, J Antimicrob Chemother, 56, 470, 10.1093/jac/dki248 Zhanel, 2004, The glycylcyclines: a comparative review with the tetracyclines, Drugs, 64, 63, 10.2165/00003495-200464010-00005 Eliopoulos, 2003, Quinupristin-dalfopristin and linezolid: evidence and opinion, Clin Infect Dis, 36, 473, 10.1086/367662 Talbot, 2006, Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America, Clin Infect Dis, 42, 657, 10.1086/499819 Appelbaum, 2005, Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria, Curr Opin Microbiol, 8, 510, 10.1016/j.mib.2005.07.001 Li, 2006, Old polymyxins are back: is resistance close?, Clin Infect Dis, 43, 663, 10.1086/506571 Falagas, 2006, Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) Gram-negative bacteria, Eur J Clin Microbiol Infect Dis, 25, 596, 10.1007/s10096-006-0191-2 Linden, 2006, Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia, Clin Infect Dis, 43, S89, 10.1086/504485 Bradley, 2007, Anti-infective research and development—problems, challenges, and solutions, Lancet Infect Dis, 7, 68, 10.1016/S1473-3099(06)70689-2 Coates, 2002, The future challenges facing the development of new antimicrobial drugs, Nature Rev Drug Discov, 1, 895, 10.1038/nrd940 Norrby, 2005, Lack of development of new antimicrobial drugs: a potential serious threat to public health, Lancet Infect Dis, 5, 115, 10.1016/S1473-3099(05)70086-4 Livermore, 2004, The need for new antibiotics, Clin Microbiol Infect, 10, 1, 10.1111/j.1465-0691.2004.1004.x Wise, 2006, Antimicrobial resistance: paradox, actions and economics, J Antimicrob Chemother, 57, 1024, 10.1093/jac/dkl138 Projan, 2004, Antibacterial drug discovery: is it all downhill from here?, Clin Microbiol Infect, 10, 18, 10.1111/j.1465-0691.2004.1006.x Bush, 2004, Antibacterial drug discovery in the 21st century, Clin Microbiol Infect, 10, 10, 10.1111/j.1465-0691.2004.1005.x Vicente, 2006, The fallacies of hope: will we discover new antibiotics to combat pathogenic bacteria in time?, FEMS Microbiol Rev, 30, 841, 10.1111/j.1574-6976.2006.00038.x Shlaes, 2007, New antibiotics—government intervention versus market forces, Microbe, 2, 56 Powers, 2004, Antimicrobial drug development—the past, the present, and the future, Clin Microbiol Infect, 10, 23, 10.1111/j.1465-0691.2004.1007.x Alanis, 2005, Resistance to antibiotics: are we in the post-antibiotic era?, Arch Med Res, 36, 697, 10.1016/j.arcmed.2005.06.009 Livermore, 2006 Gaynes, 2005, Overview of nosocomial infections caused by Gram-negative bacilli, Clin Infect Dis, 41, 848, 10.1086/432803 Cassell, 1997, Emergent antibiotic resistance: health risks and economic impact, FEMS Immunol Med Microbiol, 18, 271, 10.1111/j.1574-695X.1997.tb01055.x Wilson, 2004, Direct costs of multidrug-resistant Acinetobacter baumannii in the burn unit of a public teaching hospital, Am J Infect Control, 32, 342, 10.1016/j.ajic.2004.02.008 Loivukene, 2006, Surveillance of antimicrobial resistance of invasive pathogens: the Estonian experience, Euro Surveill, 11, 47, 10.2807/esm.11.02.00601-en Bonn, 2007, Antimicrobial resistance rising in Europe, Lancet Infect Dis, 7, 86, 10.1016/S1473-3099(07)70010-5 Streulens, 2003, The problem of resistance Gootz, 2006, The forgotten Gram-negative bacilli: what genetic determinants are telling us about the spread of antibiotic resistance, BiochemPharmacol, 71, 1073 Paterson, 2006, Resistance in Gram-negative bacteria: Enterobacteriaceae, Am J Infect Control, 34, S20, 10.1016/j.ajic.2006.05.238 Paterson, 2006, Serious infections in the intensive care unit: Pseudomonas aeruginosa and Acinetobacter baumannii, Clin Infect Dis, 43, S41, 10.1086/504473 Thomson, 2005, The threat of antibiotic resistance in Gram-negative pathogenic bacteria: beta-lactams in peril!, Curr Opin Microbiol, 8, 518, 10.1016/j.mib.2005.08.014 Bonomo, 2006, Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa, Clin Infect Dis, 43, S49, 10.1086/504477 Cornaglia Kim, 2006, Characterization of the bifunctional aminoglycoside-modifying enzyme ANT(3″)-Ii/AAC(6′)-IId from Serratia marcescens, Biochemistry, 45, 8368, 10.1021/bi060723g Robicsek, 2006, The worldwide emergence of plasmid-mediated quinolone resistance, Lancet Infect Dis, 6, 629, 10.1016/S1473-3099(06)70599-0 Robicsek, 2006, Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase, Nat Med, 12, 83, 10.1038/nm1347 Yamane K, Wachino J, Kimura K, Suzuki S, Shibata N, Arakawa Y. Novel plasmid-mediated fluoroquinolone efflux pump, Qep, identified in Escherichia coli. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA, USA; Sept 27–30, 2006. C1-586. Pachon-Ibanez, 2004, Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem, Antimicrob Agents Chemother, 48, 4479, 10.1128/AAC.48.11.4479-4481.2004 Rice, 2006, Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa, Clin Infect Dis, 43, S100, 10.1086/504487 Peleg, 2007, Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report, J Antimicrob Chemother, 59, 128, 10.1093/jac/dkl441 Chopra, 2003, Tetracyclines American Society for Microbiology. Proceedings of the 46th ICAAC. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC; Sept 27–30, 2006. Washington DC: American Society for Microbiology, 2006. American Society for Microbiology. Proceedings of the 47th ICAAC. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL; Sept 17–20, 2007. Washington DC: American Society for Microbiology, 2007. Projan, 2003, Why is big Pharma getting out of antibacterial drug discovery?, Curr Opin Microbiol, 6, 427, 10.1016/j.mib.2003.08.003 Bush, 2004, Why it is important to continue antibacterial drug discovery, ASM News, 70, 282 Finch, 2006, Antibiotic resistance—action to promote new technologies: report of an EU Intergovernmental Conference held in Birmingham, UK, 12–13 December 2005, J Antimicrob Chemother, 58, i3, 10.1093/jac/dkl373 Baquero, 2006 Projan, 2002, Antimicrobials: new solutions badly needed, Curr Opin Microbiol, 5, 463, 10.1016/S1369-5274(02)00364-8 Metlay, 2006, Antimicrobial drug resistance, regulation, and research, Emerg Infect Dis, 12, 183, 10.3201/eid1202.050078 Fernandes, 2006, Antibacterial discovery and development—the failure of success?, Nat Biotech, 24, 1497, 10.1038/nbt1206-1497 Katz, 2006, Where have all the antibiotic patents gone?, Nat Biotechnol, 24, 1529, 10.1038/nbt1206-1529 D'Costa, 2006, Sampling the antibiotic resistome, Science, 311, 374, 10.1126/science.1120800 Andersson, 2006, The biological cost of mutational antibiotic resistance: any practical conclusions?, Curr Opin Microbiol, 9, 461, 10.1016/j.mib.2006.07.002 Hurdle, 2004, Analysis of mupirocin resistance and fitness in Staphylococcus aureus by molecular genetic and structural modeling techniques, Antimicrob Agents Chemother, 48, 4366, 10.1128/AAC.48.11.4366-4376.2004 Projan, 2007, (Genome) size matters, Antimicrob Agents Chemother, 51, 1133, 10.1128/AAC.01370-06 Fournier, 2006, Comparative genomics of multidrug resistance in Acinetobacter baumannii, PLoS Genet, 2, e7, 10.1371/journal.pgen.0020007 Chopra, 2002, Exploiting current understanding of antibiotic action for discovery of new drugs, J Appl Microbiol, 92, 4S, 10.1046/j.1365-2672.92.5s1.13.x Johnstone, 2002, Seeking superbug-busters, Modern Drug Discovery, 5, 34 Barrett, 2005, Can biotech deliver new antibiotics?, Curr Opin Microbiol, 8, 498, 10.1016/j.mib.2005.08.007 Cuatrecasas, 2006, Drug discovery in jeopardy, J Clin Invest, 116, 2837, 10.1172/JCI29999 Kaiser, 2006, Biomedical research: a cure for medicine's ailments?, Science, 311, 1852, 10.1126/science.311.5769.1852 Tartaglia, 2006, Repositioning's role in drug discovery and development, Drug Discovery World, winter, 9 Besong, 2005, A de novo designed inhibitor of D-Ala-D-Ala ligase from Escherichia coli, Angew Chem Int Ed Engl, 44, 6403, 10.1002/anie.200501662 Gobec, 2007, Design, synthesis, biochemical evaluation and antimycobacterial action of phosphonate inhibitors of antigen 85C, a crucial enzyme involved in biosynthesis of the mycobacterial cell wall, Eur J Med Chem, 42, 54, 10.1016/j.ejmech.2006.08.007 Gobec, 2004, Phosphonate inhibitors of antigen 85C, a crucial enzyme involved in the biosynthesis of the Mycobacterium tuberculosis cell wall, Bioorg Med Chem Lett, 14, 3559, 10.1016/j.bmcl.2004.04.052 Horton, 2003, Macrocyclic inhibitors of the bacterial cell wall biosynthesis enzyme MurD, Bioorg Med Chem Lett, 13, 1557, 10.1016/S0960-894X(03)00176-8 Kovac, 2006, New lipophilic phthalimido- and 3-phenoxybenzyl sulfonates: inhibition of antigen 85C mycolyltransferase activity and cytotoxicity, J Enzyme Inhib Med Chem, 21, 391, 10.1080/14756360600703214 Strancar, 2006, Design, synthesis and structure-activity relationships of new phosphinate inhibitors of MurD, Bioorg Med Chem Lett, 16, 343, 10.1016/j.bmcl.2005.09.086